Interventional Radiologic Treatment of Hepatocellular Carcinoma—A Cost Analysis from the Payer Perspective
Authors:
- Charles E. RayCRCharles E. Ray
- Catherine BattagliaCBCatherine Battaglia
- Anne M. LibbyALAnne M. Libby
- Allan ProchazkaAPAllan Prochazka
- Stan XuSXStan Xu
- Brian FunakiBFBrian Funaki
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 23 (3) , 306-314
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2010
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- The burden of illness associated with hepatocellular carcinoma in the United StatesJournal of Hepatology, 2009
- Sorafenib in Liver Cancer — Just the BeginningNew England Journal of Medicine, 2008
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trialsAlimentary Pharmacology & Therapeutics, 2006
- Long‐term Follow‐up Outcome of Patients Undergoing Radiofrequency Ablation for Unresectable Hepatocellular CarcinomaWorld Journal of Surgery, 2005
- Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with CirrhosisAnnals of Surgical Oncology, 2005
- Early-Stage Hepatocellular Carcinoma in Patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency AblationRadiology, 2005
- Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term resultsEuropean Radiology, 2001